Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers
Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a critical role in cancer angiogenesis. Inhibition of VEGFR-2 activity proved effective suppression of tumour propagation. Accordingly, two series of new 3-methylquinoxaline derivatives have been designed and synthesised as VEGFR-2 inhibi...
Main Authors: | Mohammed M. Alanazi, Ibrahim H. Eissa, Nawaf A. Alsaif, Ahmad J. Obaidullah, Wael A. Alanazi, Abdullah F. Alasmari, Hussam Albassam, Hazem Elkady, Alaa Elwan |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2021.1956488 |
Similar Items
-
Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies
by: Mohammed M. Alanazi, et al.
Published: (2021-01-01) -
Further studies of the reactions of quinoxaline and 2-methylquinoxaline
by: Myers, Marcus N.
Published: (1952) -
Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers
by: Nawaf A. Alsaif, et al.
Published: (2021-01-01) -
Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies
by: Abdulmalik S. Altamimi, et al.
Published: (2021-05-01) -
Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors
by: Nashwa M. Saleh, et al.
Published: (2020-01-01)